Form 4: Celularity CEO Robert Hariri Executes RSU Vesting

Celularity Inc. CEO Robert J. Hariri acquired 3,281 shares of Class A Common Stock through the vesting of restricted stock units.

Summary

• CEO Robert J. Hariri converted 3,281 restricted stock units (RSUs) into Class A Common Stock on April 13, 2026.
• The transaction involved a tax withholding of 1,182 shares at a price of $1.28 per share.
• Following these transactions, the CEO's total beneficial ownership stands at 2,853,553 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event related to executive compensation, having no impact on the company's fundamental outlook.

Positives

• The transaction reflects the scheduled vesting of long-term equity compensation, aligning executive interests with shareholder value.

Negatives

• The filing indicates a mandatory tax withholding transaction, which is a standard administrative event rather than a market-driven sale.

Risks

• No specific operational or financial risks are disclosed in this ownership filing.

Future Outlook

The filing does not provide forward-looking financial guidance or operational outlook.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market sentiment regarding the company's clinical pipeline.

Comparison to Industry Standards

• The vesting of RSUs and subsequent tax withholding is a standard practice for executive compensation in the biotechnology sector.
• The transaction size is immaterial relative to the total shares outstanding and the CEO's total holdings.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine equity vesting event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Celularity, CELU, Insider Trading, Form 4, Robert Hariri, Equity Compensation, Biotech